

## UPCOMING FUNDING OPPORTUNITIES

### EXTERNAL OPPORTUNITIES

#### Research Professor Grants

**Purpose:** Investigators who are full professors and made significant contributions that have changed the direction of cancer care research and who expect to continue to provide leadership in their research area.

**Funder:** American Cancer Society (ACS)

**Applicant:** Mid-Career to Established in Field

**Amount:** \$80,000/yr for 5 years

**Letter of Intent Deadline:** 01 Feb 2024

#### NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

**Purpose:** The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. The special Interest is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 05 Feb 2024

#### Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

**Purpose:** The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with

quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 12 Feb 2024

#### EHR Core Research (ECR): Building Capacity in STEM Education Research (ECR: BCSER)

**Purpose:** ECR's Building Capacity in STEM Education Research (ECR: BCSER) supports projects that build investigators' capacity to carry out high-quality STEM education research that will enhance the nation's STEM education enterprise. In addition, ECR: BCSER seeks to broaden the pool of researchers who can advance knowledge regarding STEM learning and learning environments, broadening participation in STEM fields, and STEM workforce development. Researchers of races and ethnicities, genders, sexual orientations, and abilities who are currently underrepresented in their participation in STEM education research and the STEM workforce, as well as faculty at minority-serving and two-year institutions, are particularly encouraged to submit proposals. Specifically, ECR: BCSER supports activities that enable researchers to expand their areas of expertise and acquire the requisite knowledge and skills to conduct rigorous research in STEM education. Career development may be accomplished through investigator-initiated professional development and research projects or through institutes that enable researchers to integrate methodological strategies with theoretical and practical issues in STEM education.

**Funder:** National Science Foundation (NSF)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$25,000 - \$1,000,000

**Deadline:** 23 Feb 2024

# BCCC-CURE Funding Opportunities / December 18, 2023

## Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

**Purpose:** This funding opportunity announcement (FOA) calls for research on a broad range of scientific areas within NCI's Division of Cancer Control and Populations Sciences' (DCCPS) mission and portfolio, including but not limited to research in statistical and analytic methods, epidemiology and genomics, cancer survivorship, cancer-related behaviors, health care delivery, and implementation science.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$250,000/yr over 5 years

**Deadline:** 07 Mar 2024

## NSF Scholarships in Science, Technology, Engineering, and Mathematics (S-STEM)

**Purpose:** The main goal of the S-STEM program is to enable low-income students with academic ability, talent or potential to pursue successful careers in promising STEM fields. Ultimately, the S-STEM program seeks to increase the number of academically promising low-income students who graduate with a S-STEM eligible degree and contribute to the American innovation economy with their STEM knowledge. Recognizing that financial aid alone cannot increase retention and graduation in STEM, the program provides awards to institutions of higher education (IHEs) not only to fund scholarships, but also to adapt, implement, and study evidence-based curricular and co-curricular activities that have been shown to be effective supporting recruitment, retention, transfer (if appropriate), student success, academic/career pathways, and graduation in STEM.

**Funder:** National Science Foundation (NSF)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$1,000,000 - \$5,000,000 over 6 years

**Deadline:** 11 Mar 2024

## The HMTF Pilot Award Program for Myelodysplastic Syndrome Research

**Purpose:** The new Henry and Marilyn Taub Foundation (HMTF) Pilot award will provide seed money to pursue transformative ideas that can forge new scientific directions and strategies in

MDS research. While relatively short in duration, pilot awards represent a class of grants providing seed money to test novel, ground-breaking ideas and generate preliminary data typically needed for support through conventional grant mechanisms. The new HMTF Pilot Award provides funding over one-year with the goal of exploring untested strategies and disruptive new ideas. These one-year proof-of-concept studies represent new and conceptually innovative ideas that can include high-risk/high-reward projects and encourage collaborative efforts that bring in new concepts, technologies and strategies from other fields. Research must be non-incremental and not extensions of current lines of study. If successful, the data from these pilot studies will generate critical preliminary data and serve as an onramp for their continued pursuit through more conventional grant opportunities.

**Funder:** The Henry and Marilyn Taub Foundation

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$100,000

**Letter of Intent Deadline:** 11 Mar 2024

## Emerging Mathematics in Biology (eMB)

**Purpose:** The Emerging Mathematics in Biology (eMB) program seeks to stimulate fundamental interdisciplinary and potentially transformative research pertaining to the development of innovative mathematical/statistical/computational theories, tools, and modeling approaches to investigate challenging questions of great interest to biologists and public health policymakers. It supports research projects in mathematical biology that address challenging and significant biological questions through novel applications of traditional, but nontrivial, mathematical tools and methods or the development of new theories particularly from foundational mathematics and/or computational/statistical tools, including Artificial Intelligence/Deep Learning/Machine Learning (AI/DL/ML). The program emphasizes the uses of mathematical methodologies to advance our understanding of complex, dynamic, and heterogeneous biological systems at all scales (molecular, cellular, organismal, population, ecosystems, etc.).

**Funder:** National Science Foundation (NSF)

**Applicant:** Early Career and Emerging in Field /

# BCCC-CURE Funding Opportunities / December 18, 2023

Mid-Career to Established in Field

**Amount:** \$2,000,000 - \$6,000,000/yr for 3 years

**Deadline:** 11 Mar 2024

## Early Career Investigator Award

**Purpose:** METAvivor funds research that specifically addresses the mechanistic understanding, diagnosis, and/or treatment of metastatic breast cancer. METAvivor funds research focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients.

**Funder:** METAvivor

**Applicant:** Early Career and Emerging in Field

**Amount:** \$200,000 for up to 2 years

**Letter of Intent Deadline:** 12 Mar 2024

## Exceptional Project Grants

**Purpose:** Breast Cancer Alliance invites clinical doctors and research scientists at any stage of their careers, including post docs, whose current proposal is focused on breast cancer, to apply for an Exceptional Project Grant. This award recognizes creative, unique and innovative research and is open to applicants at institutions in the contiguous United States.

**Funder:** Breast Cancer Alliance

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$100,000

**Letter of Intent Deadline:** 31 Mar 2024

## Young Investigator Grants

**Purpose:** To encourage a commitment to breast cancer research, Breast Cancer Alliance invites clinical doctors and research scientists who are in the early stages of their careers, including post docs, whose current proposal is focused on breast cancer, to apply for funding for the Young Investigator Grant. This grant is open to applicants at institutions in the contiguous United States.

**Funder:** Breast Cancer Alliance

**Applicant:** Early Career and Emerging in Field

**Amount:** \$125,000 over 2 years

**Letter of Intent Deadline:** 31 Mar 2024

## Discovery Boost Grants (DBG)

**Purpose:** Discovery Boost Grants (DBG) support high-risk, high-reward exploratory cancer research across the research continuum. Investigators may focus on developing research

methodologies, establishing feasibility, or leading pilot tests. It is expected that preliminary data generated from a completed DBG will have the potential to secure additional grant funding to further the research and open new and highly innovative areas for investigation.

**Funder:** American Cancer Society (ACS)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$125,000/yr for 2 years

**Deadline:** 01 Apr 2024

## Research Scholar Grants

**Purpose:** Research Scholar Grants (RSG) provide support for independent, self-directed researchers. Applicants' institutions must provide space and other resources customary for independent investigators. Grant proposals are investigator-initiated and may pursue questions across the cancer research continuum, as long as they fit within an American Cancer Society (ACS) [priority research area](#). These grants typically contribute to the cost of salaries, consumable supplies, and other miscellaneous items required in the research.

**Funder:** American Cancer Society (ACS)

**Applicant:** Early Career and Emerging in Field

**Amount:** \$200,000/yr for 4 years

**Deadline:** 01 Apr 2024

## Postdoctoral Fellowships

**Purpose:** Postdoctoral Fellowships (PF) support new investigators in research training programs to position them for independent careers in cancer research. As part of their evaluation, peer reviewers consider how well the fellowship will broaden the applicant's research training and experience.

**Funder:** American Cancer Society (ACS)

**Applicant:** Early Career and Emerging in Field

**Amount:** \$204,000 over 3 years

**Deadline:** 01 Apr 2024

## Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

**Purpose:** This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical

## BCCC-CURE Funding Opportunities / December 18, 2023

care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. This initiative is also available through the Exploratory/Developmental Grants Phase II (R33) grant mechanism.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$150,000/yr for 3 years  
**Deadline:** 01 Apr 2024

### Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

**Purpose:** This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic, clinical, or epidemiological cancer research. The emphasis of this NOFO is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but

must be focused on improving molecular and/or cellular characterizations of cancer biology. This initiative is also available through the Exploratory/Developmental Grants Phase II (R33) grant mechanism.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$300,000/yr for 3 years  
**Deadline:** 01 Apr 2024

### Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

**Purpose:** The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$500,000/yr over 5 years  
**Deadline:** 18 Apr 2024

### Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)

**Purpose:** Through this Notice of Funding Opportunity (NOFO) entitled "Innovative Research in Cancer Nanotechnology (IRCN)", the National Cancer Institute (NCI) encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address overcoming major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets *in vivo* and/or characterization of detection and diagnostic

# BCCC-CURE Funding Opportunities / December 18, 2023

devices and sensors *in vitro*. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions. The clinical translation of these interventions is outside of scope of this NOFO.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$475,000/yr for 5 years

**Deadline:** 03 May 2024

## Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

**Purpose:** This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is designed to enable the translation of nanotechnology-based cancer interventions relying on nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are expected to mature experimental nanomedicines designed for highly relevant cancer clinical objectives with a strong potential to improve cancer treatment effectiveness. It is expected that improvement of treatment effectiveness will occur due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$475,000/yr for 4 years

**Deadline:** 17 May 2024

## National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)

**Purpose:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for

investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 25 May 2024

## Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

**Purpose:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this NOFO will support educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$150,000/yr for 2 years

**Deadline:** 25 May 2024

## Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)

**Purpose:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support

# BCCC-CURE Funding Opportunities / December 18, 2023

educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this NOFO will support educational activities with a primary focus on courses for skills development.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$300,000/yr for 5 years  
**Deadline:** 25 May 2024

## Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed)

**Purpose:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on research experiences.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$300,000/yr for 5 years  
**Deadline:** 25 May 2024

## Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

**Purpose:** The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of \$250,001 or greater in any of the Federal fiscal years 2018-2020. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field /

Mid-Career to Established in Field  
**Amount:** \$25,000 - \$250,000  
**Deadline:** 03 Jun 2024

## Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)

**Purpose:** The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$50,000 - \$600,000  
**Deadline:** 03 Jun 2024

## High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)

**Purpose:** The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. Instruments supported include, but are not limited to, biomedical imagers, high throughput robotic screening systems, X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, and cell sorters.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$750,001 - \$2,000,000  
**Deadline:** 03 Jun 2024

## Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions,

## BCCC-CURE Funding Opportunities / December 18, 2023

practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged. This initiative is also available through the Small Research Grants ([R03](#)) and Exploratory/Developmental Grants ([R21](#)) mechanisms.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 05 Jun 2024

### [Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem \(R01 Clinical Trial Optional\)](#)

**Purpose:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies. This initiative is also available through the Exploratory/Developmental Grants ([R21](#)) grant mechanism.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field /

Mid-Career to Established in Field

**Amount:** \$500,000/yr for 5 years

**Deadline:** 05 Jun 2024

### [Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer \(R01 Clinical Trial Not Allowed\)](#)

**Purpose:** The purpose of this Funding Opportunity Announcement (FOA) is to support basic research that elucidates mechanisms by which the human microbiome inhibits or enhances anti-tumor immune responses, and to identify potential novel molecular targets for cancer prevention strategies. Applications should be focused on delineating how host interactions with specific microbes (or consortia) or their metabolites target immune responses that enhance or prevent inflammation-associated or sporadic tumor formation. Concentration, timing, and duration of administered beneficial microbes may alter its effectiveness and thus those parameters should be rigorously addressed in the application. This initiative is also available through the Exploratory/Developmental Grants ([R21](#)) grant mechanism.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 05 Jun 2024

### [Assay development and screening for discovery of chemical probes, drugs or immunomodulators \(R01 Clinical Trial Not Allowed\)](#)

**Purpose:** Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to stimulate research in discovery and development of novel, small molecules for cancer. Molecules discovered through this NOFO may be used to probe cancer biology, to validate cancer targets, or as the basis for optimized drugs. Stages of discovery research covered by this NOFO include: 1) development of the primary screen assay(s) and testing in an initial pilot screen; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

# BCCC-CURE Funding Opportunities / December 18, 2023

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** varies to reflect the needs of the project  
**Deadline:** 05 Jun 2024

## Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)

**Purpose:** This funding opportunity announcement (FOA) seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** varies to reflect the needs of the project  
**Deadline:** 05 Jun 2024

## Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

**Purpose:** The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) develop, integrate, optimize, validate, translate or accelerate adoption of promising tools, methods and techniques: a) that fulfill an unmet need and address specific research or clinical problem in basic, translational, and/or clinical science and practice, b) capable of enhancing our understanding of health and disease, and/or c) improve practice of medicine. Applications may propose design-directed, developmental, discovery-driven, or hypothesis-driven research, and this FOA is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** varies to reflect the needs of the project  
**Deadline:** 05 Jun 2024

## NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)

**Purpose:** The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on a) courses for skills development, b) research experiences, c) mentoring activities, d) curriculum or methods development, or e) outreach.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$250,000/yr for 5 years  
**Deadline:** 07 Jun 2024

## Broadening Opportunities for Computational Genomics and Data Science Education (UE5 Clinical Trial Not Allowed)

**Purpose:** The NIH Research Education Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this U35 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research. To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on curriculum or methods development.

**Funder:** National Institutes of Health (NIH)  
**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field  
**Amount:** \$150,000/yr for 3 years  
**Deadline:** 10 Jun 2024

## Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

**Purpose:** The purpose of this Notice of Funding Opportunity (NOFO) is to invite exploratory/developmental research grant applications (R21) for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research



## BCCC-CURE Funding Opportunities / December 18, 2023

continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, the emphasis of this NOFO is on supporting the development of novel informatics capabilities that involve a high degree of innovation that have the potential to accelerate or enhance research. To be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Projects with a significant level of data generation and/or data analysis will not be considered responsive to this funding opportunity. This initiative is also available through the Research Project Cooperative Agreements (U01) mechanism, which is focused on early-stage development from prototyping to hardening and adaptation.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$275,000 over 2 years

**Deadline:** 11 Jun 2024

### Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

**Purpose:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from both the screened and the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and other clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection

biomarkers. The proposed research project must involve use of PLCO biospecimens and may include other resources; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 11 Jun 2024

### NCI Mentored Research Scientist Development Award to Promote Diversity (K01 -Independent Clinical Trial Not Allowed)

**Purpose:** The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field

**Amount:** varies to reflect the needs of the project

**Deadline:** 12 Jun 2024

### Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)

**Purpose:** Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention. The UG3 phase will provide up to three years of support for milestone-driven initial target selection, verification of the target in clinical samples and preclinical in vivo studies, assay development, and/or assay validation for target activity, as well as on-target toxicity screening, and pilot screening of natural agents. If UG3 milestones are met, support may be provided for a full-scale screening, identification of active natural compounds, full-scale evaluation of screened individual agents, assessment of the natural product's effect in vitro and in vivo, and

# BCCC-CURE Funding Opportunities / December 18, 2023

determining the optimal dose for subsequent studies and safety testing in the UH3 phase.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$250,000 - \$400,000/yr for 3 years

**Deadline:** 13 Jun 2024

## [NIMHD Exploratory/Developmental Research Grant Program \(R21 - Clinical Trial Optional\)](#)

**Purpose:** NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$275,000 over 2 years

**Deadline:** 16 Jun 2024

## [NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 \(NCI Omnibus\) \(R03 Clinical Trial Optional\)](#)

**Purpose:** This funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$50,000/yr for 2 years

**Deadline:** 20 Jun 2024

## [Understanding Chronic Conditions Understudied Among Women \(R01 Clinical Trial Optional\)](#)

**Purpose:** The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in

biomedical Research should align with Goal 1 of the [2019-2023 Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women."

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$50,000/yr for 2 years

**Deadline:** 20 Jun 2024

## [Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery \(R01 Clinical Trials Not Allowed\)](#)

**Purpose:** This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal model and human subjects research projects are welcome; however, clinical trials are not allowed.

**Funder:** National Institutes of Health (NIH)

**Applicant:** Early Career and Emerging in Field / Mid-Career to Established in Field

**Amount:** \$350,000/yr for 4 years

**Deadline:** 21 Jun 2024

## UPCOMING EVENTS

January 17 • 12:00 - 1:00PM

### **How to Develop an Evaluation Plan for your Grant Application**

Not all grant proposals require an evaluation plan; however, in recent years most program announcements and funding opportunities stipulate an evaluation strategy or plan with specific milestones. If an evaluation plan is required, it will be listed in the program announcement. Most often, larger, more involved grant proposals always will require an evaluation plan. An outcomes evaluation is an integral part of a grant proposal that provides information to investigators and sponsors on how to improve a project during its development and implementation. A final summative evaluation provides a post-project analysis on the extent to which the project met its goals after it has been completed. This webinar will cover the following topics: What is a project evaluation? Why is it

## BCCC-CURE Funding Opportunities / December 18, 2023

needed? Should you include an evaluation plan in your proposal if it is not required? What kinds of evaluations exist and how do you choose the right evaluator for your project? Should you always employ an outside independent evaluator in your project? Should you always include a logic model? How can a logic model be helpful in the implementation of an evaluation plan?

Presenter: John Tsapogas, Director, RFCUNY APPS. *Training presented as part of the RFCUNY Brown Bag Series.* [Link to register](#)

January 24 • 12:00 - 1:00PM

### **U.S. Department of Health and Human Services (HHS)-Center for Medicare and Medicaid Services (CMS) Minority Research Grant Program (MRGP)**

MRGP provides funding opportunities to support health equity research conducted Minority Serving Institutions. The purpose of the MRGP is to support researchers at minority serving institutions that are exploring how HHS can better meet the health care needs of CMS beneficiaries. The MRGP supports research on the discovery and characterization of health processes, practices, behaviors, and burdens or issues related to CMS programs, policies, and operations, which influence health equity. Research may comprehensively address the social determinants of health that drive or influence the barriers and opportunities of populations supported by CMS benefits, services, and coverage. Research should focus

on understanding how inequities in communities impact health and may also employ participatory methods that foster equitable engagement of affected communities in research, such as the convening of community members/groups, community-based organizations, advisory groups, and service providers. MRGP goals are to 1) Develop capacity at minority serving institutions to research health disparities and social determinants of health; 2) Understand the root cause of issues – processes, practices, behaviors, and burdens – that lead to health disparities and identify replicable interventions; and 3) Strengthen CMS programs by disseminating best practices uncovered through funded research. Presenter: John Tsapogas, Director, RFCUNY APPS and Josh Brumberg, Dean for the Sciences, CUNY Graduate Center. *Training presented as part of the RFCUNY Brown Bag Series.* [Link to register](#)